Savara announces encore presentations from the phase 3 impala-2 trial of molgramostim inhalation solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at two upcoming scientific conferences

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, phase 3 impala-2 clinical trial of molgramostim in apap will be presented at the 65th congress of the german society of pneumology (dgp) in leipzig, germany taking place april 9-12 and at the 65th annual meeting of the japanese respiratory society (jrs) taking place april 11-1.
SVRA Ratings Summary
SVRA Quant Ranking